Loading news...
Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics.
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
32,410 shares were exercised and sold for a total transaction value of ~$6.0 million on February 2, 2026. After this transaction, Tabuteau directly held 7,229 shares and indirectly held 7,344,500 shares.
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March:
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and Symbravo remains uncertain.
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago.
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the fourth quarter and full year 2025 and provided a general business update.
GSA Capital Partners LLP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,767 shares of the company's stock, valued at approximately $579,000. Several other large investors have
Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either.
NVIDIA, Albemarle and Axsome Therapeutics emerge as standout plays as AI, clean energy and healthcare draw massive capital in a split 2026 market.
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and sixteen have given a buy recommendation to the company. The average 12 month
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Alkem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Alkem a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The healthcare company is set to release its fourth-quarter results later this month.